In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Novartis, Infinity team up for cancer collaboration

Executive Summary

Expanding upon their original January 2005 deal, Infinity Pharmaceuticals (developing cancer therapeutics) and Novartis will work on the discovery, development, and marketing of drugs that target the Bcl-2 protein family (including Bcl-2 and Bcl-xL) to treat cancer, including hematological cancers and solid tumors.
Deal Industry
  • Biotechnology
    • Drug Discovery Tools
      • Molecular Diversity
        • Natural Products
  • Pharmaceuticals
Deal Status
  • Terminated
Deal Type
  • Alliance
    • R+D and Marketing-Licensing
    • Includes Equity
    • Co-Promotion
    • Includes Contract

Related Companies

Advertisement
UsernamePublicRestriction

Register